Catalent (NASDAQ: CTLT) and Concordia International Corp. (NASDAQ:CXRX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.


This table compares Catalent and Concordia International Corp.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Catalent 10.02% 36.29% 7.36%
Concordia International Corp. -269.97% -83.96% -0.62%

Valuation and Earnings

This table compares Catalent and Concordia International Corp.’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Catalent $2.08 billion 2.45 $407.50 million N/A N/A
Concordia International Corp. $677.25 million 0.09 $326.58 million ($35.65) -0.03

Catalent has higher revenue and earnings than Concordia International Corp..

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Catalent and Concordia International Corp., as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Catalent 0 3 7 0 2.70
Concordia International Corp. 5 1 0 0 1.17

Catalent presently has a consensus target price of $38.60, suggesting a potential downside of 5.30%. Concordia International Corp. has a consensus target price of $8.00, suggesting a potential upside of 558.44%. Given Concordia International Corp.’s higher possible upside, analysts clearly believe Concordia International Corp. is more favorable than Catalent.

Insider & Institutional Ownership

9.1% of Concordia International Corp. shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.


Catalent beats Concordia International Corp. on 8 of the 10 factors compared between the two stocks.

Catalent Company Profile

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.

Concordia International Corp. Company Profile

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.

Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with's FREE daily email newsletter.